Buyback yield (TTM)
1.05%
Shareholder yield (TTM)
2.17%
5Y share count change
14.9%
Buyback spend (TTM)
$227.90M
Cumulative buybacks
$1.84B
Key takeaways
- STERIS (STE) repurchased about $227.90M of stock over the trailing twelve months.
- Diluted share count is up 14.9% over the last ~5 fiscal years — equity issuance and stock-based compensation are outpacing repurchases.
- TTM buyback ÷ stock-based-comp ratio of 2.43× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at +74.3% per year over the latest 5-year window.
- TTM repurchases used about 31% of free cash flow remaining after dividends.
Dividend & buyback yield over time for STERIS (STE)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for STERIS (STE)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for STERIS (STE)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for STERIS (STE)
Latest: $235.50M
Overview
As of the 2026 fiscal year, STERIS (STE) reported buyback spend of $235.50M – grew 11.4% year-over-year.
Through 2021–2026 (5 years), STERIS buyback spend delivered a +74.3% annualised rate; sustaining 2 straight years of year-over-year growth.
STERIS buyback spend peaked at $308.56M in 2023; the latest annual figure is $235.50M in 2026 (23.7% below peak).
Across the available history, buyback spend reached its high of $308.56M in 2023 and its low of $0.00 in 1991.
STERIS Buyback Spend 2026: $235.50M
STERIS buyback spend in 2026 was $235.50M, grew 11.4% from 2025.
STERIS Buyback Spend 2025: $211.32M
2025's buyback spend for STERIS came in at $211.32M, surged 1696.2% from 2024.
STERIS Buyback Spend 2024: $11.77M
STERIS posted buyback spend of $11.77M in 2024, plunged 96.2% below 2023.
STERIS Buyback Spend 2023: $308.56M
In 2023, STERIS reported buyback spend of $308.56M, surged 453.2% from 2022. This figure represents the highest annual value in the available history.
STERIS Buyback Spend 2022: $55.78M
STERIS buyback spend in 2022 was $55.78M.
See more financial history for STERIS (STE).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2026 | $235.50M | $61.70M | $173.80M | 1.09% | 0.10B | -0.4% | |
| 2025 | $211.32M | $57.40M | $153.92M | 0.95% | 0.10B | -0.3% | |
| 2024 | $11.77M | $56.53M | −$44.77M | 0.05% | 0.10B | -0.9% | |
| 2023 | $308.56M | $38.95M | $269.61M | 1.63% | 0.10B | +2.0% | |
| 2022 | $55.78M | $57.66M | −$1.88M | 0.23% | 0.10B | +14.5% | |
| 2021 | $14.65M | $25.97M | −$11.32M | 0.09% | 0.09B | +0.3% | |
| 2020 | $51.24M | $23.81M | $27.43M | 0.43% | 0.09B | +0.2% | |
| 2019 | $81.49M | $23.96M | $57.53M | 0.76% | 0.09B | -0.3% | |
| 2018 | $65.48M | $22.19M | $43.30M | 0.83% | 0.09B | -0.4% | |
| 2017 | $97.51M | $18.79M | $78.72M | 1.65% | 0.09B | +20.9% | |
| 2016 | $14.37M | $16.15M | −$1.78M | 0.24% | 0.07B | +18.6% | |
| 2015 | $30.69M | $14.92M | $15.77M | 0.73% | 0.06B | +0.5% | |
| 2014 | $25.47M | $11.10M | $14.37M | 0.90% | 0.06B | +1.5% | |
| 2013 | $8.00M | $8.92M | −$915.00K | 0.33% | 0.06B | -0.2% | |
| 2012 | $56.75M | $7.86M | $48.89M | 3.11% | 0.06B | -2.0% | |
| 2011 | $29.96M | $10.19M | $19.78M | 1.46% | 0.06B | +1.2% | |
| 2010 | $310.00K | $7.37M | −$7.06M | 0.02% | 0.06B | -0.0% | |
| 2009 | $80.47M | $7.37M | $73.10M | 5.91% | 0.06B | -7.5% | |
| 2008 | $177.17M | $0.00 | $177.17M | 10.73% | 0.06B | -2.2% | |
| 2007 | $60.17M | $0.00 | $60.17M | 3.51% | 0.07B | -4.6% | |
| 2006 | $84.15M | $0.00 | $84.15M | 5.10% | 0.07B | -1.4% | |
| 2005 | $33.87M | $0.00 | $33.87M | 1.93% | 0.07B | -1.4% | |
| 2004 | $16.61M | $0.00 | $16.61M | 0.94% | 0.07B | -0.1% | |
| 2003 | $16.07M | $0.00 | $16.07M | 0.89% | 0.07B | -0.2% | |
| 2002 | $0.00 | $0.00 | $0.00 | — | 0.07B | +7.9% | |
| 2001 | $0.00 | $0.00 | $0.00 | — | 0.07B | -5.8% | |
| 2000 | $28.71M | $0.00 | $28.71M | — | 0.07B | -1.2% | |
| 1999 | $17.70M | $0.00 | $17.70M | — | 0.07B | +2.8% | |
| 1998 | $10.10M | $0.00 | $10.10M | — | 0.07B | +1.2% | |
| 1997 | $11.40M | $0.00 | $11.40M | — | 0.07B | — | |
| 1996 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1995 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1994 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1993 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1992 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1991 | $0.00 | $0.00 | $0.00 | — | — | — |
- 2026$235.50M
- 2025$211.32M
- 2024$11.77M
- 2023$308.56M
- 2022$55.78M
- 2021$14.65M
- 2020$51.24M
- 2019$81.49M
- 2018$65.48M
- 2017$97.51M
- 2016$14.37M
- 2015$30.69M
- 2014$25.47M
- 2013$8.00M
- 2012$56.75M
- 2011$29.96M
- 2010$310.00K
- 2009$80.47M
- 2008$177.17M
- 2007$60.17M
- 2006$84.15M
- 2005$33.87M
- 2004$16.61M
- 2003$16.07M
- 2002$0.00
- 2001$0.00
- 2000$28.71M
- 1999$17.70M
- 1998$10.10M
- 1997$11.40M
- 1996$0.00
- 1995$0.00
- 1994$0.00
- 1993$0.00
- 1992$0.00
- 1991$0.00
Buybacks vs stock-based compensation for STERIS (STE)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 2.43×.
Buybacks vs dividends (share of cash returned) for STERIS (STE)
How STERIS splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as STERIS, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $980.00M | |
| $216.35M | |
| $0.00 | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $216.35M
- $0.00
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $730.60M (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation